Form 4: NewAmsterdam Pharma Co N.V. Executive Kling Disposes of Shares Following RSU Vesting

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., reports the acquisition and disposal of ordinary shares related to the vesting of restricted stock units (RSUs).

Summary

• On March 26, 2025, Douglas F. Kling, the Chief Operating Officer of NewAmsterdam Pharma Co N.V., engaged in transactions involving the company's ordinary shares.
• Kling acquired 16,539 shares through the vesting of Restricted Stock Units (RSUs).
• Simultaneously, Kling disposed of 16,539 shares at prices ranging from $22.75 to $23.20 per share.
• These shares were sold to cover tax withholding obligations arising from the RSU vesting.
• Following these transactions, Kling directly owns 44,000 ordinary shares.
• The RSUs were granted on March 26, 2025, as earnout RSUs related to a business combination agreement from July 25, 2022.
• These RSUs were contingent on achieving a clinical development milestone within five years of the Closing Date, and Kling's right to receive them became fixed on the Closing Date.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about share ownership changes.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions. It provides transparency into the trading activities of company executives and their holdings in the company. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
• The sale of shares could exert minor downward pressure on the share price.

Key Dates

Keywords

Form 4, NewAmsterdam Pharma, NAMS, Insider Trading, Douglas Kling, RSU, Share Disposal, Beneficial Ownership